IF THERE'S AN ELEMENT OF FAILURE, TRY TO FAIL FAST
Business Today|January 12, 2020
The over $22 billion pharma major AstraZeneca has seen one of the most remarkable turnarounds in drug research history. With 144 projects in clinical trials and 16 new molecular entities in final Phase-III trials, it boasts of a new drugs pipeline bigger than that of rivals Pfizer and Roche – both more than double its size in revenue. Yet, the world’s 14th largest pharma company faces multiple challenges, two of which are Brexit and the US-China trade war (18% revenue from China and 30% from the US). Business Today’s Rajeev Dubey caught up with AstraZeneca’s Non-executive Chairman, Leif Johansson, during his recent India visit. Edited Excerpts:
Rajeev Dubey
IF THERE'S AN ELEMENT OF FAILURE, TRY TO FAIL FAST

AstraZeneca’s research turnaround is unique in global drug history. What is the secret sauce?

I became chairman in 2012 and decided to replenish the pipeline. So, we hired Pascal Soriot (the company’s Executive Director and Chief Executive Officer). He and his team have done a much better evaluation of the projects we have. He not only brought discipline in the process, but also sharp decision making, and unsentimental decisions on which projects have to go. If there’s an element of risk or failure, then try to fail fast. By doing that, you free up resources for projects that we are standing behind.

In 2012, we spent almost 90 per cent of our R&D internally. Now, overall, what we are doing in our R&D with small or medium-sized companies, if you add transactions by molecules selling projects ( joint molecule development projects), then the number is probably 50-50. So, a combination of much better decision-making and opening up has meant four-fold productivity of new drug discovery. That is the remarkable effect Pascal Soriot’s team has had on the group.

What has been your experience in drug research costs? How do you optimise costs? What’s your experience spending dollars internally and working with other partners, including Sun Pharma in India?

The cost of making a drug is always increasing. The way to offset that is to try to fail fast. The trick is to get the mix right. We are using digital tools – in India it is called AI – which is very good to screen molecules. Small chemical molecules have 25-50 atoms per molecule. In biological molecules, we are talking about 250,000 atoms per molecule. To screen these complex structures, you need a lot of computing power and digitalisation.

Denne historien er fra January 12, 2020-utgaven av Business Today.

Start din 7-dagers gratis prøveperiode på Magzter GOLD for å få tilgang til tusenvis av utvalgte premiumhistorier og 9000+ magasiner og aviser.

Denne historien er fra January 12, 2020-utgaven av Business Today.

Start din 7-dagers gratis prøveperiode på Magzter GOLD for å få tilgang til tusenvis av utvalgte premiumhistorier og 9000+ magasiner og aviser.

FLERE HISTORIER FRA BUSINESS TODAYSe alt
"Moving to cloud helped us grow❞
Business Today India

"Moving to cloud helped us grow❞

What was the problem you were grappling with?

time-read
1 min  |
November 24, 2024
She's Got Time
Business Today India

She's Got Time

MORE WOMEN ARE BECOMING WATCH CONNOISSEURS, SEEKING OUT BOTH JEWELLED AND TECHNICAL WATCHES FOR THEIR STYLE AND CRAFTSMANSHIP

time-read
3 mins  |
November 24, 2024
RISING STAR
Business Today India

RISING STAR

PARUL GULATI IS a name that's been steadily gaining prominence in the Indian entertainment industry after she appeared on season 2 of Shark Tank in 2023. She has become a multifaceted personality who effortlessly transitions between acting and entrepreneurship.

time-read
1 min  |
November 24, 2024
Building on a Legacy
Business Today India

Building on a Legacy

WHEN ZAHABIYA KHORAKIWALA stepped into her role as Managing Director of Wockhardt Hospitals over a decade ago, she confronted formidable challenges that have since turned into achievements.

time-read
1 min  |
November 24, 2024
LEADER IN INNOVATION
Business Today India

LEADER IN INNOVATION

AS FEDEX'S PRESIDENT (Middle East, Indian subcontinent and Africa), Kami Viswanathan has a lot on her plate.

time-read
1 min  |
November 24, 2024
WAITING IN THE WINGS
Business Today India

WAITING IN THE WINGS

Here are those who missed out as they have not yet completed a year in office; they'll be strong contenders in 2025

time-read
1 min  |
November 24, 2024
A DECENT PROPOSAL
Business Today India

A DECENT PROPOSAL

IN TODAY'S WORLD OF TRYING TO CREATE AN EQUITABLE SPACE, BOTH MEN AND WOMEN CONTRIBUTE TO THEIR HOUSEHOLDS. WOMEN ARE ENCOURAGED TO HAVE THEIR OWN SAVINGS POOL AND INVESTMENT ROUTINE. GIVEN THIS, HOW SHOULD FUTURE BRIDES APPROACH FINANCIAL PLANNING?

time-read
5 mins  |
November 24, 2024
Women and the STEM Bias
Business Today India

Women and the STEM Bias

EMPOWERING WOMEN IN STEM WILL NOT ONLY BENEFIT INDIVIDUALS, BUT ALSO STRENGTHEN THE ENTIRE INDUSTRY, DRIVING INNOVATION AND PROGRESS.

time-read
3 mins  |
November 24, 2024
ROCKET WOMEN
Business Today India

ROCKET WOMEN

WOMEN IN INDIA ARE NOT ONLY VENTURING INTO SPACE BUT ARE ALSO STARTING TO SPEARHEAD THE COUNTRY'S EFFORTS IN THE GLOBAL SPACE RACE.

time-read
6 mins  |
November 24, 2024
ONE STEP FORWARD
Business Today India

ONE STEP FORWARD

THE NUMBER OF WOMEN INDEPENDENT DIRECTORS IS GROWING STEADILY, BUT IT'S A LONG WAY FROM GENDER PARITY. MUCH MORE NEEDS TO BE DONE TO BREAK THE GLASS CEILING IN BOARDROOMS.

time-read
6 mins  |
November 24, 2024